Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$8.06
▼ $0.03 (-0.4%)
Market data updated: 09/19 09:04 AM
Fundamentals updated: 09/18/2026
News analyzed: 09/19/2026
Market Cap
$369.93M
Day Range
$7.86 - $8.23
52-Week Range
$4.88 - $25.96
Beta
—
Next Earnings
04.11.2026
Support
$7.62
Resistance
$25.42
BIOA is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+61.8% (1Y)
Strengths: 7/28 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 66.2%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$37.57 vs. price $8.06 (-566.1%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
41
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
46
Quality
55
Value
38
Momentum
19
Risk
46
Sentiment
86
Fundamental
34
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of BioAge Labs has primarily focused on its clinical progress and financial performance. The company made headlines in September 2026 for initiating a Phase 2 trial (QUELL-DME) of its oral NLRP3 inhibitor, BGE-102, for diabetic macular edema, marking a key milestone in its pipeline. Analysts, including BTIG’s Thomas Shrader, reiterated a "Buy" rating with a $40 price target, while Q2 2026 results showed improved revenue ($2.45M vs. estimates) despite ongoing losses, though financial updates were overshadowed by the trial announcement.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about BioAge Labs, Inc.. News trend score: 86. Reason: 7 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
33
🎯 Conviction (vs. Emotion)
52
Psychology
57
Fundamentals
34
Technical
19
Valuation
38
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-61%
Market Narrative
47
Fundamental Reality
52
Narrative Gap
-5
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s dominant **Loss Aversion** (72) reflects deep psychological resistance to further losses, amplified by a prolonged drawdown (-38.9% in 3 months). Herding (61) suggests traders are passively mirroring peers rather than driving action, while muted volatility (0.54x ATR) implies cautious, not desperate, behavior. The narrative gap (0) means sentiment (98/100) and reality diverge minimally, but the extreme negative momentum (-10.8% ROC) and oversold conditions (RSI 34) may signal exhaustion of selling pressure. The key question: *Will traders finally accept losses, or will the stock’s underperformance trigger forced liquidation?*
Updated: 09/08/2026, 04:13 PM
What could change this?
👥 What the crowd believes
"BTIG reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target"
"Bioage Labs reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.60) by 3.33 percent"
📈 5D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 100/100
🔴 Weakest match
Philip Fisher — 0/100
🗣️ Why do they disagree?
This stock splits methodologies into two starkly opposing camps: the bullish, growth-oriented investors like Peter Lynch and Walter Bagehot—who see it as a high-potential opportunity, either because the price hasn’t reflected its growth potential or because its liquidity ensures resilience—versus the more cautious or skeptical approaches, such as Philip Fisher and Thorstein Veblen, who dismiss it outright for lacking Fisher’s signature quality or Veblen’s concern over unchecked growth motives. Meanwhile, the middle ground features a mix of tactical optimism (e.g., Nelson and Schwager, who see cyclical or reward/risk advantages) and guarded caution (e.g., Marks and Loeb, who acknowledge potential but flag risks like overvaluation or volatility). The divide underscores a tension between those prioritizing fundamental growth or defensive stability and those wary of either overpaying or betting on speculative trends.
Peter Lynch
One Up on Wall Street (1989)
🟢 100
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 99
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 99
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 84
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 81
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 79
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 78
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 60
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 58
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 53
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 42
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 38
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 31
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 13
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 0
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Based on the last 279 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 10 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-1031.5%
Net Margin
-896.1%
EBITDA Margin
-1031.5%
ROE
-29.6%
ROA
-27.3%
ROIC
—
EPS
-$2.24
Cash
$188.89M
Total Debt
$2.65M
Current Ratio
14.24
Debt/Equity
0.01
How is Fair Value calculated? →
Current Price
$8.06
Estimated Fair Value (DCF)
-$37.57
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-566.1%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $-90.58M | $-83.10M |
| 2 | 8.1% | $-97.94M | $-82.43M |
| 3 | 6.3% | $-104.06M | $-80.35M |
| 4 | 4.4% | $-108.61M | $-76.95M |
| 5 | 2.5% | $-111.33M | $-72.36M |
Base FCF (last actual year)
$-82.35M
Terminal Value
$-1.76B
Present Value of Terminal Value
$-1.14B
Enterprise Value
$-1.54B
Net Debt
$-186.24M
Equity Value
$-1.35B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$7.57
Tangible Book Value per Share (Tangible NAV)
$7.57
Sentiment based on basic keywords (not AI) — 7 positive, 12 neutral, 1 negative out of the last 20 articles.
SeekingAlpha · 16.9.2026
SeekingAlpha · 9.9.2026
Benzinga · 9.9.2026
MT Newswires · 8.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
Benzinga · 8.9.2026
Benzinga · 8.9.2026
SeekingAlpha · 5.9.2026
Yahoo · 2.9.2026
GlobeNewswire · 2.9.2026
Yahoo · 31.8.2026
PR Newswire · 31.8.2026
Benzinga · 6.8.2026
Zacks · 6.8.2026
GlobeNewswire · 5.8.2026
Benzinga · 5.8.2026
Benzinga · 3.8.2026
Stocktwits · 31.7.2026
ChartMill · 31.7.2026
BioAge Labs, Inc. (BIOA) currently has a StockIQ AI score of 41/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
BIOA currently scores 41/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, BIOA's estimated fair value is -$37.57, which is 566.1% below the current price of $8.06. This is one valuation model among several signals in the fair-value category, not a price target.
BIOA's technical score is 19/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 66.2%; Debt/equity: 0.01; Current ratio: 14.24.
Based on the real signals StockIQ computed: Estimated fair value: -$37.57 vs. price $8.06 (-566.1%); Operating margin: -1031.5% (negative); Net margin: -896.1% (negative).
StockIQ has no recorded dividend payment history for BIOA.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 3 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 4,065 | -4,065 | — |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 4,290 | -4,290 | — |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 7,861 | -7,861 | — |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 4,290 | +4,290 | $10.85 |
| Barton Shane | Open Market Sale | 30.6.2026 | 20,216 | -20,216 | $25.19 |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 4,000 | -4,000 | — |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 7,861 | +7,861 | $4.38 |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 4,065 | +4,065 | $4.30 |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 4,000 | +4,000 | $8.39 |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 4,290 | +4,290 | $10.85 |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 8,290 | +4,000 | $8.39 |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 12,355 | +4,065 | $4.30 |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 20,216 | +7,861 | $4.38 |
| Barton Shane | Open Market Sale | 30.6.2026 | 0 | -20,216 | $25.19 |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 13,299 | -4,290 | — |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 17,016 | -4,000 | — |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 26,977 | -4,065 | — |
| Barton Shane | Exercise of Derivative Securities | 30.6.2026 | 67,941 | -7,861 | — |
| Barton Shane | Exercise of Derivative Securities | 29.6.2026 | 8,958 | +8,958 | $4.30 |
| Barton Shane | Exercise of Derivative Securities | 29.6.2026 | 7,261 | -7,261 | — |
| Barton Shane | Exercise of Derivative Securities | 29.6.2026 | 9,301 | -9,301 | — |
| Barton Shane | Open Market Sale | 29.6.2026 | 42,350 | -42,350 | $25.21 |
| Barton Shane | Exercise of Derivative Securities | 29.6.2026 | 14,198 | +14,198 | $4.38 |
| Barton Shane | Exercise of Derivative Securities | 29.6.2026 | 7,261 | +7,261 | $8.39 |
| Barton Shane | Exercise of Derivative Securities | 29.6.2026 | 9,301 | +9,301 | $10.85 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,722,576 shares short as of 2026-08-31 · vs. 2,565,606 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
39.8% of trading volume this week was short selling, vs. 44.1% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology